Wetherby Asset Management Inc. boosted its position in Celgene Co. (NASDAQ:CELG) by 1.8% during the first quarter, according to its most recent Form 13F filing with the SEC. The fund owned 15,027 shares of the biopharmaceutical company’s stock after buying an additional 270 shares during the period. Wetherby Asset Management Inc.’s holdings in Celgene were worth $1,870,000 as of its most recent filing with the SEC.
A number of other institutional investors have also recently added to or reduced their stakes in CELG. Motco boosted its position in Celgene by 306.9% in the first quarter. Motco now owns 822 shares of the biopharmaceutical company’s stock worth $102,000 after buying an additional 620 shares during the period. Carroll Financial Associates Inc. boosted its position in Celgene by 70.9% in the first quarter. Carroll Financial Associates Inc. now owns 964 shares of the biopharmaceutical company’s stock worth $119,000 after buying an additional 400 shares during the period. Oakworth Capital Inc. boosted its position in Celgene by 60.9% in the first quarter. Oakworth Capital Inc. now owns 1,089 shares of the biopharmaceutical company’s stock worth $136,000 after buying an additional 412 shares during the period. Barnett & Company Inc. boosted its position in Celgene by 18.3% in the third quarter. Barnett & Company Inc. now owns 1,130 shares of the biopharmaceutical company’s stock worth $118,000 after buying an additional 175 shares during the period. Finally, Reilly Financial Advisors LLC boosted its position in Celgene by 15.3% in the first quarter. Reilly Financial Advisors LLC now owns 1,211 shares of the biopharmaceutical company’s stock worth $151,000 after buying an additional 161 shares during the period. Hedge funds and other institutional investors own 77.68% of the company’s stock.
Shares of Celgene Co. (CELG) opened at 118.19 on Friday. The firm has a market capitalization of $92.29 billion, a P/E ratio of 44.38 and a beta of 1.74. Celgene Co. has a 12 month low of $94.42 and a 12 month high of $127.64. The firm’s 50-day moving average is $119.60 and its 200 day moving average is $119.63.
Celgene (NASDAQ:CELG) last released its earnings results on Thursday, April 27th. The biopharmaceutical company reported $1.68 earnings per share for the quarter, beating the Zacks’ consensus estimate of $1.47 by $0.21. The firm had revenue of $2.96 billion for the quarter, compared to analysts’ expectations of $3.04 billion. Celgene had a net margin of 17.80% and a return on equity of 77.95%. The company’s quarterly revenue was up 17.8% on a year-over-year basis. During the same period in the previous year, the company earned $1.32 earnings per share. On average, equities research analysts anticipate that Celgene Co. will post $7.29 EPS for the current year.
TRADEMARK VIOLATION NOTICE: This piece of content was first reported by sleekmoney and is the sole property of of sleekmoney. If you are viewing this piece of content on another domain, it was illegally stolen and reposted in violation of United States and international copyright & trademark laws. The legal version of this piece of content can be read at https://sleekmoney.com/celgene-co-celg-position-increased-by-wetherby-asset-management-inc/1899015.html.
A number of equities analysts have recently commented on the stock. Cantor Fitzgerald set a $159.00 price objective on shares of Celgene and gave the stock a “buy” rating in a research note on Thursday, April 27th. Leerink Swann restated a “market perform” rating on shares of Celgene in a research note on Monday, March 20th. Cann restated a “buy” rating and set a $148.00 price objective on shares of Celgene in a research note on Tuesday, April 4th. Canaccord Genuity set a $156.00 price objective on shares of Celgene and gave the stock a “buy” rating in a research note on Tuesday, June 6th. Finally, Robert W. Baird restated an “outperform” rating and set a $162.00 price objective on shares of Celgene in a research note on Wednesday, April 19th. One equities research analyst has rated the stock with a sell rating, six have given a hold rating, nineteen have assigned a buy rating and one has assigned a strong buy rating to the stock. The company has a consensus rating of “Buy” and a consensus price target of $139.05.
In other Celgene news, Director James J. Loughlin sold 9,250 shares of the business’s stock in a transaction dated Monday, May 1st. The shares were sold at an average price of $124.00, for a total value of $1,147,000.00. Following the transaction, the director now directly owns 32,169 shares in the company, valued at $3,988,956. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, Director Gilla Kaplan sold 14,033 shares of the company’s stock in a transaction that occurred on Thursday, March 30th. The shares were sold at an average price of $123.83, for a total transaction of $1,737,706.39. Following the sale, the director now owns 73,109 shares in the company, valued at $9,053,087.47. The disclosure for this sale can be found here. 0.97% of the stock is owned by insiders.
Celgene Corporation is an integrated global biopharmaceutical company. The Company, together with its subsidiaries, is engaged in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation.
Want to see what other hedge funds are holding CELG? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Celgene Co. (NASDAQ:CELG).
This story was originally published by sleekmoney (https://sleekmoney.com) and is the sole property of sleekmoney. If you are reading this article on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. You can view the original version of this story at https://sleekmoney.com/celgene-co-celg-position-increased-by-wetherby-asset-management-inc/1899015.html
Receive News & Ratings for Celgene Co. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene Co. and related companies with MarketBeat.com's FREE daily email newsletter.